WVE Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-02-17 | Vargeese Chandra | officer: Chief Technology Officer, Head of Platform Discovery Sciences | 295,400 | A-Award | A | 295,400 | 4.75 | 1,403,150.00 |
| 2023-02-17 | BOLNO PAUL | director, officer: President and CEO | 771,000 | A-Award | A | 771,000 | 4.75 | 3,662,250.00 |
| 2023-02-17 | Francis Chris | officer: SVP, Corporate Development, Head of Emerging Areas | 244,700 | A-Award | A | 244,700 | 4.75 | 1,162,325.00 |
| 2023-02-17 | Moran Kyle | officer: Chief Financial Officer | 272,700 | A-Award | A | 272,700 | 4.75 | 1,295,325.00 |
| 2023-02-16 | Vargeese Chandra | officer: Chief Technology Officer, Head of Platform Discovery Sciences | 106,624 | S-Sale | D | 10,249 | 4.03 | 41,303.47 |
| 2023-02-16 | BOLNO PAUL | director, officer: President and CEO | 407,425 | S-Sale | D | 29,400 | 4.04 | 118,776.00 |
| 2023-02-16 | Francis Chris | officer: SVP, Corporate Development, Head of Emerging Areas | 79,714 | S-Sale | D | 10,258 | 4.03 | 41,339.74 |
| 2023-02-16 | Moran Kyle | officer: Chief Financial Officer | 79,751 | S-Sale | D | 9,729 | 4.04 | 39,305.16 |
| 2022-10-27 | Verdine Gregory L. | director | 163,467 | A-Award | A | 163,467 | 4.37 | 714,350.79 |
| 2022-08-15 | Tan Aik Na | director | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-08-15 | CORRIGAN MARK | director | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-08-15 | TAKANASHI KEN | director, 10 percent owner | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-08-15 | Wagner Heidi L | director | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-08-15 | Verdine Gregory L. | director | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-08-15 | HENRY CHRISTIAN O | director | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-08-15 | Rawcliffe Adrian | director | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-08-15 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner | 21,000 | A-Award | A | 21,000 | 3.50 | 73,500.00 |
| 2022-07-25 | Moran Kyle | officer: Chief Financial Officer | 60,000 | A-Award | A | 60,000 | 2.83 | 169,800.00 |
| 2022-07-25 | Francis Chris | officer: SVP, Corporate Development, Head of Emerging Areas | 45,000 | A-Award | A | 45,000 | 2.83 | 127,350.00 |
| 2022-07-25 | BOLNO PAUL | director, officer: President and CEO | 180,000 | A-Award | A | 180,000 | 2.83 | 509,400.00 |
| 2022-07-25 | Panzara Michael A. | officer: Chief Medical Officer, Head of Therapeutics Discovery and Development | 60,000 | A-Award | A | 60,000 | 2.83 | 169,800.00 |
| 2022-07-25 | Vargeese Chandra | officer: Chief Technology Officer, Head of Platform Discovery Sciences | 60,000 | A-Award | A | 60,000 | 2.83 | 169,800.00 |
| 2022-06-16 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner | 7,093,656 | P-Purchase | A | 7,093,656 | 0.00 | 709.37 |
| 2022-06-16 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner | 17,202,009 | P-Purchase | A | 9,480,052 | 2.15 | 20,382,111.80 |
| 2022-05-05 | Vargeese Chandra | officer: Chief Technology Officer, Head of Platform Discovery Sciences | 111,095 | S-Sale | D | 16,714 | 1.72 | 28,748.08 |
| 2022-05-05 | Francis Chris | officer: SVP, Corporate Development, Head of Emerging Areas | 89,972 | S-Sale | D | 10,867 | 1.72 | 18,691.24 |
| 2022-05-05 | Moran Kyle | officer: Chief Financial Officer | 84,567 | S-Sale | D | 5,021 | 1.72 | 8,636.12 |
| 2022-05-05 | BOLNO PAUL | director, officer: President and CEO | 436,825 | S-Sale | D | 33,501 | 1.72 | 57,621.72 |
| 2022-05-05 | Panzara Michael A. | officer: Chief Medical Officer, Head of Therapeutics Discovery and Development | 109,103 | S-Sale | D | 16,714 | 1.72 | 28,748.08 |
| 2022-05-04 | Vargeese Chandra | officer: Chief Technology Officer, Head of Platform Discovery Sciences | 127,809 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2022-05-04 | Francis Chris | officer: SVP, Corporate Development, Head of Emerging Areas | 100,839 | A-Award | A | 32,500 | 0.00 | 0.00 |
| 2022-05-04 | Moran Kyle | officer: Chief Financial Officer | 89,588 | A-Award | A | 15,000 | 0.00 | 0.00 |
| 2022-05-04 | BOLNO PAUL | director, officer: President and CEO | 470,326 | A-Award | A | 92,500 | 0.00 | 0.00 |
| 2022-05-04 | Panzara Michael A. | officer: Chief Medical Officer, Head of Therapeutics Discovery and Development | 125,817 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2022-02-16 | Moran Kyle | officer: Chief Financial Officer | 74,588 | S-Sale | D | 9,204 | 2.31 | 21,261.24 |
| 2022-02-16 | Francis Chris | officer: SVP, Corporate Development, Head of Emerging Areas | 68,339 | S-Sale | D | 10,123 | 2.31 | 23,384.13 |
| 2022-02-16 | Vargeese Chandra | officer: Chief Technology Officer | 77,809 | S-Sale | D | 10,603 | 2.32 | 24,598.96 |
| 2022-02-16 | BOLNO PAUL | director, officer: President and CEO | 377,826 | S-Sale | D | 33,150 | 2.32 | 76,908.00 |
| 2022-02-16 | Panzara Michael A. | officer: Chief Medical Officer, Head of Therapeutics Discovery and Development | 75,817 | S-Sale | D | 10,603 | 2.31 | 24,492.93 |
| 2022-01-01 | Vargeese Chandra | officer: Chief Technology Officer | 200,000 | A-Award | A | 200,000 | 3.14 | 628,000.00 |
| 2022-01-01 | Francis Chris | officer: SVP, Corporate Development, Head of Emerging Areas | 150,000 | A-Award | A | 150,000 | 3.14 | 471,000.00 |
| 2022-01-01 | BOLNO PAUL | director, officer: President and Chief Executive Officer | 600,000 | A-Award | A | 600,000 | 3.14 | 1,884,000.00 |
| 2022-01-01 | Panzara Michael A. | officer: Chief Medical Officer, Head of Therapeutics Discovery and Development | 200,000 | A-Award | A | 200,000 | 3.14 | 628,000.00 |
| 2022-01-01 | Moran Kyle | officer: Chief Financial Officer | 175,000 | A-Award | A | 175,000 | 3.14 | 549,500.00 |
| 2021-08-16 | CORRIGAN MARK | director | 21,000 | A-Award | A | 21,000 | 5.97 | 125,370.00 |
| 2021-08-16 | Rawcliffe Adrian | director | 42,000 | A-Award | A | 42,000 | 5.97 | 250,740.00 |
| 2021-08-16 | Verdine Gregory L. | director | 42,000 | A-Award | A | 42,000 | 5.97 | 250,740.00 |
| 2021-08-16 | TAKANASHI KEN | director, 10 percent owner | 42,000 | A-Award | A | 42,000 | 5.97 | 250,740.00 |
| 2021-08-16 | HENRY CHRISTIAN O | director | 42,000 | A-Award | A | 42,000 | 5.97 | 250,740.00 |
| 2021-08-16 | Tan Aik Na | director | 21,000 | A-Award | A | 21,000 | 5.97 | 125,370.00 |
| 2021-08-16 | Wagner Heidi L | director | 21,000 | A-Award | A | 21,000 | 5.97 | 125,370.00 |
| 2021-08-16 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner | 42,000 | A-Award | A | 42,000 | 5.97 | 250,740.00 |
| 2021-04-01 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner | 7,573,613 | J-Other | A | 768,431 | 5.61 | 4,310,897.91 |
| 2021-04-01 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner | 201,594 | J-Other | A | 201,594 | 5.61 | 1,130,942.34 |
| 2021-03-24 | Moran Kyle | officer: Chief Financial Officer | 80,792 | M-Exempt | A | 10,930 | 2.48 | 27,106.40 |
| 2021-03-24 | Moran Kyle | officer: Chief Financial Officer | 25,000 | M-Exempt | D | 10,930 | 2.48 | 27,106.40 |
| 2021-02-16 | Moran Kyle | officer: Chief Financial Officer | 69,862 | S-Sale | D | 1,722 | 10.57 | 18,201.54 |
| 2021-02-16 | Vargeese Chandra | officer: Senior VP, Drug Discovery | 85,412 | S-Sale | D | 3,145 | 10.57 | 33,242.65 |
| 2021-02-16 | Panzara Michael A. | officer: Chief Medical Officer | 86,420 | S-Sale | D | 2,929 | 10.57 | 30,959.53 |
| 2021-02-16 | BOLNO PAUL | director, officer: President and CEO | 410,976 | S-Sale | D | 11,205 | 10.57 | 118,436.85 |
| 2021-02-16 | Francis Chris | officer: See Remarks | 78,462 | S-Sale | D | 2,698 | 10.57 | 28,517.86 |
| 2021-02-01 | Moran Kyle | officer: Chief Financial Officer | 71,584 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2021-02-01 | Moran Kyle | officer: Chief Financial Officer | 50,000 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2021-02-01 | Vargeese Chandra | officer: Senior VP, Drug Discovery | 88,557 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2021-02-01 | Vargeese Chandra | officer: Senior VP, Drug Discovery | 50,000 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2021-02-01 | Panzara Michael A. | officer: Chief Medical Officer | 89,349 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2021-02-01 | Panzara Michael A. | officer: Chief Medical Officer | 50,000 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2021-02-01 | BOLNO PAUL | director, officer: President and CEO | 422,181 | A-Award | A | 150,000 | 0.00 | 0.00 |
| 2021-02-01 | BOLNO PAUL | director, officer: President and CEO | 200,000 | A-Award | A | 200,000 | 10.48 | 2,096,000.00 |
| 2021-02-01 | Francis Chris | officer: See Remarks | 81,160 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2021-02-01 | Francis Chris | officer: See Remarks | 50,000 | A-Award | A | 50,000 | 10.48 | 524,000.00 |
| 2020-09-15 | BOLNO PAUL | director, officer: President and CEO | 372,181 | M-Exempt | A | 100,000 | 2.48 | 248,000.00 |
| 2020-09-15 | BOLNO PAUL | director, officer: President and CEO | 272,181 | S-Sale | D | 100,000 | 2.48 | 248,000.00 |
| 2020-09-15 | BOLNO PAUL | director, officer: President and CEO | 97,778 | M-Exempt | D | 100,000 | 2.48 | 248,000.00 |
| 2020-08-25 | BOLNO PAUL | director, officer: President and CEO | 297,181 | M-Exempt | A | 25,000 | 2.48 | 62,000.00 |
| 2020-08-25 | BOLNO PAUL | director, officer: President and CEO | 272,181 | S-Sale | D | 25,000 | 2.48 | 62,000.00 |
| 2020-08-25 | BOLNO PAUL | director, officer: President and CEO | 197,778 | M-Exempt | D | 25,000 | 2.48 | 62,000.00 |
| 2020-08-18 | Rawcliffe Adrian | director | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-08-18 | CORRIGAN MARK | director | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-08-18 | Pott Amy | director | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-08-18 | Kolchinsky Peter | director, 10 percent owner | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-08-18 | Verdine Gregory L. | director | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-08-18 | Tan Aik Na | director | 21,000 | A-Award | A | 21,000 | 9.13 | 191,730.00 |
| 2020-08-18 | HENRY CHRISTIAN O | director | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-08-18 | Wagner Heidi L | director | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-08-18 | TAKANASHI KEN | director, 10 percent owner | 10,500 | A-Award | A | 10,500 | 9.13 | 95,865.00 |
| 2020-07-02 | BOLNO PAUL | director, officer: President and CEO | 315,249 | S-Sale | D | 4,509 | 10.82 | 48,787.38 |
| 2020-07-02 | BOLNO PAUL | director, officer: President and CEO | 272,181 | S-Sale | D | 43,068 | 10.26 | 441,877.68 |
| 2020-07-02 | BOLNO PAUL | director, officer: President and CEO | 372,181 | M-Exempt | A | 100,000 | 2.48 | 248,000.00 |
| 2020-07-02 | BOLNO PAUL | director, officer: President and CEO | 368,102 | S-Sale | D | 4,079 | 10.91 | 44,501.89 |
| 2020-07-02 | BOLNO PAUL | director, officer: President and CEO | 222,778 | M-Exempt | D | 100,000 | 2.48 | 248,000.00 |
| 2020-03-03 | Vargeese Chandra | officer: Senior VP, Drug Discovery | 36,000 | A-Award | A | 36,000 | 8.17 | 294,120.00 |
| 2020-03-03 | BOLNO PAUL | director, officer: President and CEO | 63,000 | A-Award | A | 63,000 | 8.17 | 514,710.00 |
| 2020-03-03 | Gaiero David G | officer: Interim CFO | 18,000 | A-Award | A | 18,000 | 8.17 | 147,060.00 |
| 2020-03-03 | Panzara Michael A. | officer: Chief Medical Officer | 36,000 | A-Award | A | 36,000 | 8.17 | 294,120.00 |
| 2020-03-03 | Francis Chris | officer: See Remarks | 36,000 | A-Award | A | 36,000 | 8.17 | 294,120.00 |
| 2020-02-18 | BOLNO PAUL | director, officer: President and CEO | 319,758 | S-Sale | D | 11,451 | 7.85 | 89,890.35 |
| 2020-02-18 | Francis Chris | officer: See Remarks | 31,160 | S-Sale | D | 2,708 | 7.85 | 21,257.80 |
| 2020-02-18 | Panzara Michael A. | officer: Chief Medical Officer | 39,349 | S-Sale | D | 2,981 | 7.85 | 23,400.85 |
| 2020-02-18 | Vargeese Chandra | officer: Senior VP, Drug Discovery | 37,057 | S-Sale | D | 3,188 | 7.85 | 25,025.80 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.